Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from EBOS Group Limited ( (AU:EBO) ).
EBOS Group director Stuart McLauchlan has increased his holding of ordinary shares through the company’s dividend reinvestment plan, according to a disclosure filed with the NZX. The transaction saw McLauchlan receive 134 additional shares on 27 March 2026, taking his interest from 5,186 to 5,320 shares, for a consideration of NZ$2,960.06.
The shares will be registered under JBWere (NZ) Nominees Limited and the transaction did not occur during a closed trading period under EBOS’s securities dealing policy. The notice underscores ongoing director participation in the dividend reinvestment plan, signalling continued alignment between board members and shareholder interests through incremental equity accumulation.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$29.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a New Zealand-listed company operating in the healthcare and animal care sectors, supplying pharmaceuticals, medical devices and related services across Australasian markets. The group also distributes products to pharmacies, hospitals and veterinary channels, positioning it as a key intermediary in regional healthcare and animal health supply chains.
Average Trading Volume: 154,755
Technical Sentiment Signal: Sell
Current Market Cap: A$3.82B
For an in-depth examination of EBO stock, go to TipRanks’ Overview page.